263 related articles for article (PubMed ID: 25604916)
1. GPR40 agonists for the treatment of type 2 diabetes: life after 'TAKing' a hit.
Mancini AD; Poitout V
Diabetes Obes Metab; 2015 Jul; 17(7):622-9. PubMed ID: 25604916
[TBL] [Abstract][Full Text] [Related]
2. CPL207280, a Novel G Protein-Coupled Receptor 40/Free Fatty Acid Receptor 1-Specific Agonist, Shows a Favorable Safety Profile and Exerts Antidiabetic Effects in Type 2 Diabetic Animals.
Bazydlo-Guzenda K; Buda P; Matloka M; Mach M; Stelmach F; Dzida R; Smuga D; Hucz-Kalitowska J; Teska-Kaminska M; Vialichka V; Dubiel K; Kaminska B; Wieczorek M; Pieczykolan J
Mol Pharmacol; 2021 Oct; 100(4):335-347. PubMed ID: 34349026
[TBL] [Abstract][Full Text] [Related]
3. GPR40 agonists for the treatment of type 2 diabetes mellitus: The biological characteristics and the chemical space.
Chen C; Li H; Long YQ
Bioorg Med Chem Lett; 2016 Dec; 26(23):5603-5612. PubMed ID: 27825762
[TBL] [Abstract][Full Text] [Related]
4. Activation of GPR40 as a therapeutic target for the treatment of type 2 diabetes.
Burant CF
Diabetes Care; 2013 Aug; 36 Suppl 2(Suppl 2):S175-9. PubMed ID: 23882043
[TBL] [Abstract][Full Text] [Related]
5. A novel antidiabetic drug, fasiglifam/TAK-875, acts as an ago-allosteric modulator of FFAR1.
Yabuki C; Komatsu H; Tsujihata Y; Maeda R; Ito R; Matsuda-Nagasumi K; Sakuma K; Miyawaki K; Kikuchi N; Takeuchi K; Habata Y; Mori M
PLoS One; 2013; 8(10):e76280. PubMed ID: 24130766
[TBL] [Abstract][Full Text] [Related]
6. Combining the G-protein-coupled receptor 40 agonist fasiglifam with sitagliptin improves glycaemic control in patients with type 2 diabetes with or without metformin: A randomized, 12-week trial.
Peng XV; Marcinak JF; Raanan MG; Cao C
Diabetes Obes Metab; 2017 Aug; 19(8):1127-1134. PubMed ID: 28239939
[TBL] [Abstract][Full Text] [Related]
7. GPR40: a therapeutic target for mediating insulin secretion (review).
Feng XT; Leng J; Xie Z; Li SL; Zhao W; Tang QL
Int J Mol Med; 2012 Dec; 30(6):1261-6. PubMed ID: 23023155
[TBL] [Abstract][Full Text] [Related]
8. GPR40-induced insulin secretion by the novel agonist TAK-875: first clinical findings in patients with type 2 diabetes.
Araki T; Hirayama M; Hiroi S; Kaku K
Diabetes Obes Metab; 2012 Mar; 14(3):271-8. PubMed ID: 22051148
[TBL] [Abstract][Full Text] [Related]
9. GPR40-Mediated G
Rives ML; Rady B; Swanson N; Zhao S; Qi J; Arnoult E; Bakaj I; Mancini A; Breton B; Lee SP; Player MR; Pocai A
Mol Pharmacol; 2018 Jun; 93(6):581-591. PubMed ID: 29572336
[TBL] [Abstract][Full Text] [Related]
10. Discovery of Potent and Orally Bioavailable GPR40 Full Agonists Bearing Thiophen-2-ylpropanoic Acid Scaffold.
Li H; Huang Q; Chen C; Xu B; Wang HY; Long YQ
J Med Chem; 2017 Apr; 60(7):2697-2717. PubMed ID: 28277660
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of fasiglifam (TAK-875), a G protein-coupled receptor 40 agonist, in Japanese patients with type 2 diabetes inadequately controlled by diet and exercise: a randomized, double-blind, placebo-controlled, phase III trial.
Kaku K; Enya K; Nakaya R; Ohira T; Matsuno R
Diabetes Obes Metab; 2015 Jul; 17(7):675-81. PubMed ID: 25787200
[TBL] [Abstract][Full Text] [Related]
12. TAK-875, an orally available G protein-coupled receptor 40/free fatty acid receptor 1 agonist, enhances glucose-dependent insulin secretion and improves both postprandial and fasting hyperglycemia in type 2 diabetic rats.
Tsujihata Y; Ito R; Suzuki M; Harada A; Negoro N; Yasuma T; Momose Y; Takeuchi K
J Pharmacol Exp Ther; 2011 Oct; 339(1):228-37. PubMed ID: 21752941
[TBL] [Abstract][Full Text] [Related]
13. Modulating GPR40: therapeutic promise and potential in diabetes.
Poitout V; Lin DC
Drug Discov Today; 2013 Dec; 18(23-24):1301-8. PubMed ID: 24051395
[TBL] [Abstract][Full Text] [Related]
14. TAK-875, a GPR40/FFAR1 agonist, in combination with metformin prevents progression of diabetes and β-cell dysfunction in Zucker diabetic fatty rats.
Ito R; Tsujihata Y; Matsuda-Nagasumi K; Mori I; Negoro N; Takeuchi K
Br J Pharmacol; 2013 Oct; 170(3):568-80. PubMed ID: 23848179
[TBL] [Abstract][Full Text] [Related]
15. GPR40 Agonists for the Treatment of Type 2 Diabetes Mellitus: Benefits and Challenges.
Mohammad S
Curr Drug Targets; 2016; 17(11):1292-300. PubMed ID: 26648068
[TBL] [Abstract][Full Text] [Related]
16. G-protein coupled receptor 40 agonists as novel therapeutics for type 2 diabetes.
Choi YJ; Shin D; Lee JY
Arch Pharm Res; 2014 Apr; 37(4):435-9. PubMed ID: 24234912
[TBL] [Abstract][Full Text] [Related]
17. [Discovery and development of a selective GPR40/FFAR1 agonist, fasiglifam, for treatment of type 2 diabetes mellitus].
Tsujihata Y
Nihon Yakurigaku Zasshi; 2014 Aug; 144(2):59-63. PubMed ID: 25109517
[No Abstract] [Full Text] [Related]
18. Structural basis for GPR40 allosteric agonism and incretin stimulation.
Ho JD; Chau B; Rodgers L; Lu F; Wilbur KL; Otto KA; Chen Y; Song M; Riley JP; Yang HC; Reynolds NA; Kahl SD; Lewis AP; Groshong C; Madsen RE; Conners K; Lineswala JP; Gheyi T; Saflor MD; Lee MR; Benach J; Baker KA; Montrose-Rafizadeh C; Genin MJ; Miller AR; Hamdouchi C
Nat Commun; 2018 Apr; 9(1):1645. PubMed ID: 29695780
[TBL] [Abstract][Full Text] [Related]
19. Recent Updates on Free Fatty Acid Receptor 1 (GPR-40) Agonists for the Treatment of Type 2 Diabetes Mellitus.
Rani L; Grewal AS; Sharma N; Singh S
Mini Rev Med Chem; 2021; 21(4):426-470. PubMed ID: 33100202
[TBL] [Abstract][Full Text] [Related]
20. The Role and Future of FFA1 as a Therapeutic Target.
Ghislain J; Poitout V
Handb Exp Pharmacol; 2017; 236():159-180. PubMed ID: 27807697
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]